Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

SYNTEX EXITING BEAUTY CARE: FERMODYL, RILLING, DERMETICS TO TURNER HALL CORP., a private New York firm led by a group of cosmetics execs and investors associated with the Bass family of Fort Worth, Texas. The purchase, for an undisclosed sum, was announced by Turner Hall Oct. 9. Divestiture of the professional hair, skin, and nail care lines, which contributed only about $600,000 of Syntex' total $177.7 mil. in fiscal 1983 net income, effectively removes the pharmaceutical and diagnostics firm from the beauty care industry, a spokesperson said. Syntex lost an earlier agreement to sell Fermodyl to Clairol. Syntex will "record a gain on the sale, and will additionally receive oryalties from future sale of the products," the company said. In addition to acquiring the lines, Turner Hall will lease and operate Syntex' primary beauty care production facility in Newburgh, NY. Syntex has retained distribution rights to the relatively small line of Eugene/Galia French professional hair treatment products, although the company expects it to be gradually phased out, the spokesperson noted.4

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts